(ADLS) Adbvanced Life Sciences gets orphan drug designation from FDA for its metastatic melanoma indicated treatment.
(BCS) Barclays indicated down 2% pre-market on loss exposure to outside loans.
(BNI) Burlington Nothern Santa Fe stake boosted by Warren Buffett’s Berkshire Hathaway.
(COCO) Corinthian Colleges $0.04 EPS vs $0.04 est.
(HGSI) Human Genome announced it received a $40 million milestone payment related to Albuferon development from Novartis.
(MHS) Medco paying $1.5 Billion to acquired PolyMedica (PLMD) at $53 per share.
(PLMD) PolyMedica is being acquired by Medco (MHS) at $53 per share.
(SNDA) Shanda Interactive trading up 2.5% after beating earnings expectations; CFO is leaving.
(TRMB) Trimble Navigation is partnering to launch a new precision solution for farmers.
(UNH) UnitedHealth and Sierra Health Services (SIE) has received approval of their merger from Nevada’s Division of Insurance.
(VICL) Vical will begin Phase I trials of DNA vaccine against H5N1 pandemic influenza.
As you can tell, the news is getting pretty thin out there…….
Jon C. Ogg
August 28, 2007
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
